BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Y, Wu C. Traditional chinese medicine in ameliorating diabetic kidney disease via modulating gut microbiota. Integr Med Nephrol Androl 2021;8:8. [DOI: 10.4103/imna.imna_28_21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y. Recent advances of gut microbiota in chronic kidney disease patients. Exploration of Medicine. [DOI: 10.37349/emed.2022.00090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu Z, Guan C, Li C, Zhang N, Yang C, Xu L, Zhou B, Zhao L, Luan H, Man X, Xu Y. Tilianin Reduces Apoptosis via the ERK/EGR1/BCL2L1 Pathway in Ischemia/Reperfusion-Induced Acute Kidney Injury Mice. Front Pharmacol 2022;13:862584. [DOI: 10.3389/fphar.2022.862584] [Reference Citation Analysis]
3 Wang Y, Feng H, Nie X, Zhang Y, Zou L, Li X, Yu X, Zhao Y. Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy. Front Pharmacol 2022;13:907108. [DOI: 10.3389/fphar.2022.907108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Cao G, Miao H, Wang YN, Chen DQ, Wu XQ, Chen L, Guo Y, Zou L, Vaziri ND, Li P, Zhao YY. Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacol Sin 2022. [PMID: 35577910 DOI: 10.1038/s41401-022-00914-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Yu X, Sun Q, Zhang Y, Zou L, Zhao Y. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol 2022;13:860588. [DOI: 10.3389/fphar.2022.860588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]